Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

THR 149

Next Previous
Drug Profile

THR 149

Alternative Names: THR-149

Latest Information Update: 22 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bicycle Therapeutics
  • Developer Bicycle Therapeutics; Oxurion
  • Class Bicyclic peptides; Eye disorder therapies; Peptides; Small molecules
  • Mechanism of Action Plasma kallikrein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic macular oedema

Most Recent Events

  • 20 Nov 2023 Efficacy and adverse events data from phase II KALAHARI trial in Diabetic macular edema released by Oxurion
  • 28 Sep 2023 Oxurion completes the phase II KALAHARI trial in Diabetic macular oedema (In adults, In the elderly, Treatment-experienced) in USA, Italy, Czech Republic, France, Germany, Slovakia, Spain, UK (Intravitreous) (EudraCT2019-001506-17) (NCT04527107)
  • 13 Jun 2023 Oxurion completes enrolment in its Phase-II clinical trials in Diabetic macular oedema (In adults, In the elderly, Treatment-experienced) in the US, Italy, Czechia, France, Germany, Slovakia, Spain, UK (Intravitreous) (EudraCT2019-001506-17) (NCT04527107)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top